|
[Related PubMed/MEDLINE]
Total Number of Papers: 364
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: mpMRI |
| Long Form |
: multiparametric MRI |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies. |
AUC |
| 2 |
2020 |
3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy. |
csPCa, MRGB, PI-RADSv2.1 |
| 3 |
2020 |
68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future? |
--- |
| 4 |
2020 |
A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection. |
AUC, CDRs, EM, MRI, PCa, PI-RADS, PSA, PSAD, US |
| 5 |
2020 |
A deep dive into understanding tumor foci classification using multiparametric MRI based on convolutional neural network. |
ADC, CNN, DCE, DW, PDW, T2W, WELM |
| 6 |
2020 |
A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50ng/ml. |
AUC, csPCa, MRI, ROC, SB, TB |
| 7 |
2020 |
A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy. |
DILs, IMPT, NTCP, OAR, PBS, SIB, TCP |
| 8 |
2020 |
Accuracy of abbreviated multiparametric MRI-derived protocols in predicting local staging of prostate cancer in men undergoing radical prostatectomy. |
aMRI, CI, cT2W, DCE, DWI, NPV, PCa, RP, sT2, tT2W |
| 9 |
2020 |
Accuracy of multiparametric MRI in distinguishing the breast malignant lesions from benign lesions: a meta-analysis. |
DCE-MRI, DWI |
| 10 |
2020 |
An Exploratory Study of Dose Escalation vs Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. |
HIFU, IQR, PSA |
| 11 |
2020 |
Apical periurethral transition zone lesions: MRI and histology findings. |
TZ |
| 12 |
2020 |
Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends. |
ML |
| 13 |
2020 |
Assessment of DCE Utility for PCa Diagnosis Using PI-RADS v2.1: Effects on Diagnostic Accuracy and Reproducibility. |
AUC, DCE-MRI, DWI, PCa, PI-RADS, ROC, T2W |
| 14 |
2020 |
Brain extraction on MRI scans in presence of diffuse glioma: Multi-institutional performance evaluation of deep learning methods and robust modality-agnostic training. |
DL, MRI |
| 15 |
2020 |
Can Extraprostatic Extension Be Predicted by Tumor-Capsule Contact Length in Prostate Cancer? Relationship With International Society of Urological Pathology Grade Groups. |
EPE, ISUP, RP, TCL |
| 16 |
2020 |
Can transrectal prostate ultrasound compete with multiparametric MRI in the detection of clinically significant prostate cancer? |
TRUS |
| 17 |
2020 |
Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in Glioblastoma. |
CaPTk, GBM, MRI, PFS, RP |
| 18 |
2020 |
Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation. |
AUC, MRI-US, PCa, PI-RADS, PSA, PSAD, PV, XGBoost |
| 19 |
2020 |
Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4-20ng/ml before the initial biopsy. |
PCa, PSA, ROC |
| 20 |
2020 |
Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. |
AUC, bpMRI, CSPC, DCE-MRI, DWI, MRGB, PI-RADS v2.1, PSA, T2 WI |
| 21 |
2020 |
Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. |
--- |
| 22 |
2020 |
Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features. |
ADC, GrG, PC, PCa, UA, VOIs |
| 23 |
2020 |
Comparison of Real-Time Virtual Sonography Navigation Versus BioJet Navigation on Magnetic Resonance Imaging-Guided Prostate Needle Biopsy: A Single Institutional Analysis. |
AEs, PCa, PZ, RVS, TB, TRUS, TZ |
| 24 |
2020 |
Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey. |
MRtb, PCa |
| 25 |
2020 |
Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. |
GG, RP, TZ |
| 26 |
2020 |
Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer. |
AS, PI-RADS |
| 27 |
2020 |
Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy. |
DILs, STAPLE, TRUS |
| 28 |
2020 |
Education of prostate MR imaging: commentary. |
--- |
| 29 |
2020 |
Evaluation of Apparent Diffusion Coefficient as a Predictor of Grade Reclassification in Men on Active Surveillance for Prostate Cancer. |
ADC, AS, GG, GR |
| 30 |
2020 |
Extraprostatic extension in prostate cancer: primer for radiologists. |
ADT, EPE, RP, RT |
| 31 |
2020 |
Feasibility of integrating computer-aided diagnosis with structured reports of prostate multiparametric MRI. |
CAD |
| 32 |
2020 |
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis. |
PRISMA |
| 33 |
2020 |
Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis. |
PRISMA |
| 34 |
2020 |
Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy. |
--- |
| 35 |
2020 |
Imaging Biochemical Recurrence After Prostatectomy: Where Are We Headed? |
PSMA |
| 36 |
2020 |
In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? |
SUV |
| 37 |
2020 |
Influence of the Location and Zone of Tumor in Prostate Cancer Detection and Localization on 3-T Multiparametric MRI Based on PI-RADS Version 2. |
PCa, PI-RADSv2, PZ, WMHP |
| 38 |
2020 |
Limitations of abdominopelvic CT and multiparametric MR imaging for detection of lymph node metastases prior to radical prostatectomy. |
LN, MUSIC, NPV, PCa, PPV, RP |
| 39 |
2020 |
Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. |
MRI, NAFL, NAFLD, NASH |
| 40 |
2020 |
MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI. |
bpMRI, CI, csPCa, PSAD, ROC |
| 41 |
2020 |
Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. |
AI |
| 42 |
2020 |
Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. |
AS, FUS-GB, GS, NPV, PCa, PPV |
| 43 |
2020 |
Multiparametric MRI and Whole Slide Image-Based Pretreatment Prediction of Pathological Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Multicenter Radiopathomic Study. |
LARC, RPS, TRG, WSI |
| 44 |
2020 |
Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. |
ADC, ADT, DCE, PCa, RCB, TROI/NROI |
| 45 |
2020 |
Multiparametric MRI as a Non-Invasive Monitoring Tool for Children with Autoimmune Hepatitis. |
AIH |
| 46 |
2020 |
Multiparametric MRI for prostate cancer diagnosis: current status and future directions. |
--- |
| 47 |
2020 |
Multiparametric MRI-Based Radiomics for Prostate Cancer Screening With PSA in 4-10 ng/mL to Reduce Unnecessary Biopsies. |
AUC, PCa, PSA, PSAD, ROIs |
| 48 |
2020 |
Multiparametric MRI-Based Radiomics Nomogram for Predicting Lymph Node Metastasis in Early-Stage Cervical Cancer. |
ADC, CE, CI, DWI, FS-T2 WI, LASSO, LNM, ROC-AUC, T1 WI |
| 49 |
2020 |
Multiparametric MRI-Based Radiomics Nomogram for Predicting Lymphovascular Space Invasion in Endometrial Carcinoma. |
AUC, CI, DWI, EMC, LASSO, LVSI, ROC |
| 50 |
2020 |
Multiparametric-MRI-Based Radiomics Model for Differentiating Primary Central Nervous System Lymphoma From Glioblastoma: Development and Cross-Vendor Validation. |
ADCs, AUC, CE-T1 WI, DWI, GBM, PCNSL |
| 51 |
2020 |
New options for increasing the sensitivity, specificity and scope of synergistic contrast magnetic resonance imaging (scMRI) using Multiplied, Added, Subtracted and/or FiTted (MASTIR) pulse sequences. |
CSF, DIR, fMRI, GBCAs, IR, MASTIR, MASTIR, MR, MRI, PGSE, scMRI, scMRI, SIR, TE, TI, TPs |
| 52 |
2020 |
Patient-Centered Outcomes From Multiparametric MRI and MRI-Guided Biopsy for Prostate Cancer: A Systematic Review. |
CENTRAL, PCOs |
| 53 |
2020 |
Pattern of relapse and dosimetric analysis of a single dose 19Gy HDR-brachytherapy phase II trial. |
DIL |
| 54 |
2020 |
Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy. |
GTVs, LEAD, MRI |
| 55 |
2020 |
PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. |
FFBF, NCCN, PI-RADS, RT |
| 56 |
2020 |
PI-RADS Version 2.1: A Critical Review (AJR Special Series on Radiology Reporting and Data Systems). |
PI-RADS |
| 57 |
2020 |
Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen PET-computed tomography and multiparametric MRI. |
DIL, PET-CT, PSMA, PSMA-TV, TL-PSMA |
| 58 |
2020 |
Prognostic value of seminal vesicle invasion on preoperative multi-parametric magnetic resonance imaging in pathological stage T3b prostate cancer. |
BCR, PCa, RP, SVI |
| 59 |
2020 |
Prospective Evaluation of 18F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. |
GG, PSA, PSMA, SUV |
| 60 |
2020 |
Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. |
AUC ROC, bpMRI, DCE, DWI, EPE, MRI, PCa, T2W |
| 61 |
2020 |
Prostate MR: pitfalls and benign lesions. |
--- |
| 62 |
2020 |
Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. |
AUC, BCR, CAPRA, MSKCC, RALP |
| 63 |
2020 |
Prostatitis, the Great Mimicker of Prostate Cancer: Can We Differentiate Them Quantitatively With Multiparametric MRI? |
ADC, PCa, TTP, Ve, Vp |
| 64 |
2020 |
Radiomics Based on Multiparametric Magnetic Resonance Imaging to Predict Extraprostatic Extension of Prostate Cancer. |
ADC, AUC, DCE, DWI, EPE, LASSO, PCa, T2WI |
| 65 |
2020 |
Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer. |
MRSI, PET |
| 66 |
2020 |
Role of multiparametric prostate MRI in the management of prostate cancer. |
TRUS |
| 67 |
2020 |
Role of pre-biopsy multiparametric MRI in prostate cancer diagnosis: Evidence from the literature. |
PI-RADS |
| 68 |
2020 |
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response. |
ADT, MRD, RP |
| 69 |
2020 |
Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. |
eLND, hrPC, PBR, PC |
| 70 |
2020 |
Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging. |
ADC, APC |
| 71 |
2020 |
Staging of bladder cancer with multiparametric MRI. |
--- |
| 72 |
2020 |
The performance of intravoxel-incoherent motion diffusion-weighted imaging derived hypoxia for the risk stratification of prostate cancer in peripheral zone. |
ADC, AUC, Ds, fp, GG, ISUP, IVIM, PCa, PZ, SVM |
| 73 |
2020 |
The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer. |
CEUS, HIFU, PSA |
| 74 |
2020 |
The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer. |
CRT, HNSCC, HSV, nonHSV |
| 75 |
2020 |
The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer. |
BPH, DRE, PCa, PSA, PSAD, STURS-PB, TRUS |
| 76 |
2020 |
Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice? |
--- |
| 77 |
2020 |
Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life. |
EPIC, GI, GU, HDR, HRQoL, IB-VMAT, IPSS |
| 78 |
2020 |
Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning. |
--- |
| 79 |
2020 |
Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment. |
CNN, csPCa, DCA, PSAD |
| 80 |
2020 |
Utilization of imaging for staging in bladder cancer: is there a role for MRI or PET-computed tomography? |
MIBC, NMIBC, PET-CT |
| 81 |
2020 |
Vesical Imaging-Reporting and Data System for Multiparametric MRI to Predict the Presence of Muscle Invasion for Bladder Cancer. |
AUC, CI, DCEI, DWI, MIBC, NPV, PPV, VI-RADS |
| 82 |
2020 |
Voxel-based supervised machine learning of peripheral zone prostate cancer using noncontrast multiparametric MRI. |
AUROC, DTI, DWI, MRI, SVM, T2WI |
| 83 |
2020 |
Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI. |
IMRT, TCP |
| 84 |
2020 |
What to expect from a non-suspicious prostate MRI? A review. |
NPV, PSAD |
| 85 |
2020 |
What You Need to Know Before Reading Multiparametric MRI for Prostate Cancer. |
--- |
| 86 |
2019 |
18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. |
PI-RADSv2, QALYs |
| 87 |
2019 |
68Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU. |
GS, HIFU, PCa |
| 88 |
2019 |
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. |
AUC, ePLND, LNI, MRI, PCa, RP |
| 89 |
2019 |
A review of optimal prostate biopsy: indications and techniques. |
DRE, MRI, PI-RADS2, PSA |
| 90 |
2019 |
Abbreviated Biparametric Versus Standard Multiparametric MRI for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. |
bpMRI, DOR, LR, PCa, SROC |
| 91 |
2019 |
Accuracy of multiparametric magnetic resonance imaging for detecting extracapsular extension in prostate cancer: a systematic review and meta-analysis. |
ECE, PCa, T2WI |
| 92 |
2019 |
Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging? |
AUC, MSKCC |
| 93 |
2019 |
Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer. |
3DTPMB, csPCa, TPMB |
| 94 |
2019 |
Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study. |
IHC, T2W |
| 95 |
2019 |
Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer. |
--- |
| 96 |
2019 |
Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy. |
--- |
| 97 |
2019 |
Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. |
GS, GU, PCa, WMHP |
| 98 |
2019 |
Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy. |
DILs, HDR-BT, ROs, TRUS |
| 99 |
2019 |
Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging. |
ACC, AUC, CTE, DWI, SC, SGCT |
| 100 |
2019 |
Clinically significant prostate cancer detection on MRI: A radiomic shape features study. |
csPCa, ROC, SAVR |
|
A Search Service for Abbreviation / Long Form
